Literature DB >> 31507071

Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity.

Hakan Babaoğlu1, Jessica Li2, Daniel Goldman2, Laurence S Magder3, Michelle Petri2.   

Abstract

OBJECTIVE: Lupus low disease activity state (LLDAS) is a potential treat-to-target goal in systemic lupus erythematosus (SLE). This study determined predictors of time to reach LLDAS in a longitudinal cohort.
METHODS: Patients were grouped according to LLDAS status at cohort entry. Those who did not satisfy LLDAS at cohort entry were analyzed prospectively. The Kaplan-Meier approach was used to estimate the time to LLDAS. Cox regression was used to identify patient characteristics that were associated with time to LLDAS.
RESULTS: The probability of LLDAS attainment within 1 year was 52% for Caucasians, 36% for African Americans, and 33% for SLE patients with renal involvement. The median time to LLDAS was 1.1 years. In multivariable models, African American ethnicity, baseline prednisone >10 mg daily, hypocomplementemia, baseline damage, and baseline renal activity remained significant predictors of longer time to attain LLDAS, while disease duration <1 year and cutaneous activity were associated with earlier attainment.
CONCLUSION: LLDAS is potentially attainable in the majority of SLE patients. The time to LLDAS was found to be longer in African American patients with SLE. Characteristics of African American patients with SLE, such as renal activity and hypocomplementemia, were also independent predictors of slower attainment of LLDAS. These findings point to the need to include African American patients with SLE in both clinical and pharmaceutical research.
© 2019, American College of Rheumatology.

Entities:  

Mesh:

Year:  2020        PMID: 31507071      PMCID: PMC6992499          DOI: 10.1002/acr.24063

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  50 in total

1.  Predictors of survival in systemic lupus erythematosus.

Authors:  Nuntana Kasitanon; Laurence S Magder; Michelle Petri
Journal:  Medicine (Baltimore)       Date:  2006-05       Impact factor: 1.889

2.  Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.

Authors:  Michelle Petri; Laurence S Magder
Journal:  Arthritis Rheumatol       Date:  2018-11       Impact factor: 10.995

3.  Mortality in systemic lupus erythematosus.

Authors:  S Bernatsky; J-F Boivin; L Joseph; S Manzi; E Ginzler; D D Gladman; M Urowitz; P R Fortin; M Petri; S Barr; C Gordon; S-C Bae; D Isenberg; A Zoma; C Aranow; M-A Dooley; O Nived; G Sturfelt; K Steinsson; G Alarcón; J-L Senécal; M Zummer; J Hanly; S Ensworth; J Pope; S Edworthy; A Rahman; J Sibley; H El-Gabalawy; T McCarthy; Y St Pierre; A Clarke; R Ramsey-Goldman
Journal:  Arthritis Rheum       Date:  2006-08

4.  Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual.

Authors:  G S Alarcón; G McGwin; A A Bartolucci; J Roseman; J Lisse; B J Fessler; H M Bastian; A W Friedman; J D Reveille
Journal:  Arthritis Rheum       Date:  2001-12

5.  Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.

Authors:  Josep Ordi-Ros; Luis Sáez-Comet; Mercedes Pérez-Conesa; Xavier Vidal; Francesca Mitjavila; Antoni Castro Salomó; Jordi Cuquet Pedragosa; Vera Ortiz-Santamaria; Montserrat Mauri Plana; Josefina Cortés-Hernández
Journal:  Ann Rheum Dis       Date:  2017-04-27       Impact factor: 19.103

6.  Severe lupus nephritis: racial differences in presentation and outcome.

Authors:  Stephen M Korbet; Melvin M Schwartz; Joni Evans; Edmund J Lewis
Journal:  J Am Soc Nephrol       Date:  2006-12-13       Impact factor: 10.121

7.  Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004.

Authors:  Candace H Feldman; Linda T Hiraki; Jun Liu; Michael A Fischer; Daniel H Solomon; Graciela S Alarcón; Wolfgang C Winkelmayer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2013-03

8.  Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.

Authors:  Margherita Zen; Luca Iaccarino; Mariele Gatto; Francesca Saccon; Maddalena Larosa; Anna Ghirardello; Leonardo Punzi; Andrea Doria
Journal:  Ann Rheum Dis       Date:  2017-09-26       Impact factor: 19.103

Review 9.  The Representation of Gender and Race/Ethnic Groups in Randomized Clinical Trials of Individuals with Systemic Lupus Erythematosus.

Authors:  Titilola Falasinnu; Yashaar Chaichian; Michelle B Bass; Julia F Simard
Journal:  Curr Rheumatol Rep       Date:  2018-03-17       Impact factor: 4.592

10.  Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort.

Authors:  Ioanna Giannakou; Katerina Chatzidionysiou; Laurence S Magder; Noemi Györi; Ronald van Vollenhoven; Michelle A Petri
Journal:  Lupus Sci Med       Date:  2018-11-02
View more
  4 in total

1.  Cardiac conduction disturbances in rheumatologic disease: a cross-sectional study.

Authors:  Louis Gerges; Kyla D'Angelo; David Bass; Arezoo Haghshenas; Daniel J Kersten; Manmeet Ahluwalia; Roman Zelster; Amgad N Makaryus
Journal:  Am J Cardiovasc Dis       Date:  2022-02-15

2.  Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors.

Authors:  Laurent Arnaud; Maria G Tektonidou
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

Review 3.  Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.

Authors:  Alina Dima; Ciprian Jurcut; François Chasset; Renaud Felten; Laurent Arnaud
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-02-14       Impact factor: 5.346

Review 4.  Lupus Cohorts.

Authors:  Christopher Redmond; Omer Pamuk; Sarfaraz A Hasni
Journal:  Rheum Dis Clin North Am       Date:  2021-06-10       Impact factor: 2.032

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.